News

As cell and gene therapy technologies advance, molecular assays have become essential for ensuring both speed and safety in product release. At C3i, these assays are designed with a single objective: to deliver rapid, validated data that regulators and clinicians can trust. The mycoplasma assay exemplifies this balance. Traditional compendial methods require a 28-day culture […]

In cell and gene therapy, every hour matters. The ability to test, qualify, and release a product quickly can directly impact a patient’s access to treatment. At C3i, release testing is designed to deliver fast, reliable results without compromising scientific or regulatory rigour.   C3i’s Quality Control (QC) laboratory oversees every step of product testing, […]

The C3i Center is proud to announce the appointment of Bobby Boursiquot, B.Sc., MBA, as Vice President of Commercialization. With over two decades of experience in scientific innovation and commercial growth, Mr. Boursiquot will lead the C3i Center’s initiatives to accelerate the transfer of cell and gene therapy discoveries to the marketplace. “Bobby’s rare combination […]

What Do DEL and EMA Licenses Mean for Our Day-to-Day Operations? Our commercial manufacturing licenses allow us to manufacture and test cell therapy products for the commercial market. To achieve it, all our processes were reviewed and adjusted to meet the highest regulatory standards. The level of qualification/validation of manufacturing processes, equipment, facilities, analytical methods, […]

A strategic gathering at the crossroads of innovation, regulation, and global partnerships From May 7 to 10, 2025, C3i participated in the International Society for Cell & Gene Therapy (ISCT), a major global conference held this year in New Orleans. Bringing together leading experts and organizations in the field, ISCT serves as a key hub […]

A recognition of innovation serving health and the community C3i Center is proud to have received the Prix Orchidée Innovation 2025, presented by the Chambre de commerce de l’Est de Montréal (CCEM) during the ESTim Gala held on May 8. This prestigious award celebrates our ability to turn bold ideas into tangible solutions that advance […]

An active presence at the heart of discussions on regenerative medicine On April 30, Yvan Côté, President and CEO of C3i, took part in Effervescence Montréal 2025, a key event bringing together key players from research, innovation, and the life sciences industry. Organized by ThéCell – Québec’s Cell, Tissue and Gene Therapy Network, this year’s […]

An inspiring presentation on the role of CDMOs in Québec’s biotechnology ecosystem On Monday, April 28, C3i had the pleasure of presenting its mission and expertise at INRS – Institut national de la recherche scientifique, specifically at the Armand-Frappier Santé Biotechnologie Research Centre, located in Laval. This cutting-edge center is renowned for contributing to biomedical […]

A key moment of networking and collaboration to advance research C3i was pleased to participate in the Summit for Cancer Immunotherapy, held from April 6 to 8, 2025, in Toronto, a major event organized by BioCanRx. This annual summit brings together researchers, clinicians, patient partners, and industry leaders to discuss progress in cancer immunotherapy and […]